Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?

To: richardred who wrote (1646)	4/10/2007 4:16:56 PM
From: Paul Senior	Read Replies (1) \| Respond to of 7242

Thanks for the nice response! Some good ideas in there for me to consider.

To: richardred who wrote (1646)	4/16/2007 1:00:09 PM
From: richardred	Read Replies (1) \| Respond to of 7242

SPPI-good sign, but more wait. CHICAGO, April 16 (Reuters) - Spectrum Pharmaceuticals Inc.(SPPI.O: Quote, Profile , Research) on Monday said its application for an experimental prostate cancer drug was given a priority review by U.S. regulators, triggering a $4 million payment to the company. The company said the U.S. Food and Drug Administration accepted the drug for an expedited review for satraplatin, a platinum-based oral drug for treating prostate cancer. The FDA is expected to make a decision by Aug. 15, 2007. yahoo.reuters.com